Does the media refer more to TRVI or AQST?

In the previous week, Aquestive Therapeutics had 1 more articles in the media than Trevi Therapeutics. MarketBeat recorded 3 mentions for Aquestive Therapeutics and 2 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 0.93 beat Aquestive Therapeutics' score of 0.82 indicating that Trevi Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aquestive Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AQST or ZLAB?

In the previous week, Zai Lab had 3 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 6 mentions for Zai Lab and 3 mentions for Aquestive Therapeutics. Aquestive Therapeutics' average media sentiment score of 0.82 beat Zai Lab's score of 0.26 indicating that Aquestive Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aquestive Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zai Lab 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, AQST or HCM?

HUTCHMED has higher revenue and earnings than Aquestive Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aquestive Therapeutics $44.54M 11.24 -$83.78M -$0.61 N/A HUTCHMED $548.51M 3.46 $456.91M N/A N/A

Is AQST or HCM more profitable?

HUTCHMED has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -137.08%. Company Net Margins Return on Equity Return on Assets Aquestive Therapeutics -137.08% N/A -49.33% HUTCHMED N/A N/A N/A

Do analysts recommend AQST or MESO?

Aquestive Therapeutics presently has a consensus price target of $8.80, indicating a potential upside of 120.55%. Given Aquestive Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Aquestive Therapeutics is more favorable than Mesoblast. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aquestive Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.00 Mesoblast 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33

Is AQST or MESO more profitable?

Mesoblast has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -137.08%. Company Net Margins Return on Equity Return on Assets Aquestive Therapeutics -137.08% N/A -49.33% Mesoblast N/A N/A N/A

Does the media refer more to AQST or MESO?

In the previous week, Aquestive Therapeutics and Aquestive Therapeutics both had 3 articles in the media. Aquestive Therapeutics' average media sentiment score of 0.82 beat Mesoblast's score of 0.74 indicating that Aquestive Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aquestive Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mesoblast 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Aquestive Therapeutics (AQST) Competitors

$3.99 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$3.95 -0.04 (-1.00%)

As of 07:49 PM Eastern

Compare

AQST vs. TRVI, TYRA, ZLAB, HCM, and MESO

Should you buy Aquestive Therapeutics stock or one of its competitors? MarketBeat compares Aquestive Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aquestive Therapeutics include Trevi Therapeutics (TRVI), Tyra Biosciences (TYRA), Zai Lab (ZLAB), HUTCHMED (HCM), and Mesoblast (MESO). These companies are all part of the "pharmaceutical products" industry.

How does Aquestive Therapeutics compare to Trevi Therapeutics?

Trevi Therapeutics (NASDAQ:TRVI) and Aquestive Therapeutics (NASDAQ:AQST) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

Trevi Therapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market. Comparatively, Aquestive Therapeutics has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market.

Trevi Therapeutics has higher earnings, but lower revenue than Aquestive Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Aquestive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A
Aquestive Therapeutics	$44.54M	11.24	-$83.78M	-$0.61	N/A

Trevi Therapeutics has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -137.08%. Aquestive Therapeutics' return on equity of 0.00% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-24.53%	-23.37%
Aquestive Therapeutics	-137.08%	N/A	-49.33%

Trevi Therapeutics presently has a consensus price target of $22.90, suggesting a potential upside of 70.90%. Aquestive Therapeutics has a consensus price target of $8.80, suggesting a potential upside of 120.55%. Given Aquestive Therapeutics' higher possible upside, analysts plainly believe Aquestive Therapeutics is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Aquestive Therapeutics had 1 more articles in the media than Trevi Therapeutics. MarketBeat recorded 3 mentions for Aquestive Therapeutics and 2 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 0.93 beat Aquestive Therapeutics' score of 0.82 indicating that Trevi Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trevi Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aquestive Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

95.8% of Trevi Therapeutics shares are owned by institutional investors. Comparatively, 32.5% of Aquestive Therapeutics shares are owned by institutional investors. 18.3% of Trevi Therapeutics shares are owned by company insiders. Comparatively, 6.8% of Aquestive Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Trevi Therapeutics beats Aquestive Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Aquestive Therapeutics compare to Tyra Biosciences?

Aquestive Therapeutics (NASDAQ:AQST) and Tyra Biosciences (NASDAQ:TYRA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

32.5% of Aquestive Therapeutics shares are held by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are held by institutional investors. 6.8% of Aquestive Therapeutics shares are held by insiders. Comparatively, 12.5% of Tyra Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Tyra Biosciences has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -137.08%. Aquestive Therapeutics' return on equity of 0.00% beat Tyra Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aquestive Therapeutics	-137.08%	N/A	-49.33%
Tyra Biosciences	N/A	-42.66%	-39.79%

Aquestive Therapeutics has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market. Comparatively, Tyra Biosciences has a beta of 0.75, meaning that its stock price is 25% less volatile than the broader market.

Aquestive Therapeutics presently has a consensus price target of $8.80, suggesting a potential upside of 120.55%. Tyra Biosciences has a consensus price target of $46.00, suggesting a potential upside of 80.96%. Given Aquestive Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Aquestive Therapeutics is more favorable than Tyra Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Aquestive Therapeutics has higher revenue and earnings than Tyra Biosciences. Tyra Biosciences is trading at a lower price-to-earnings ratio than Aquestive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aquestive Therapeutics	$44.54M	11.24	-$83.78M	-$0.61	N/A
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.18	N/A

In the previous week, Aquestive Therapeutics had 2 more articles in the media than Tyra Biosciences. MarketBeat recorded 3 mentions for Aquestive Therapeutics and 1 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 1.87 beat Aquestive Therapeutics' score of 0.82 indicating that Tyra Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Aquestive Therapeutics	Positive
Tyra Biosciences	Very Positive

Summary

Aquestive Therapeutics beats Tyra Biosciences on 10 of the 16 factors compared between the two stocks.

How does Aquestive Therapeutics compare to Zai Lab?

Aquestive Therapeutics (NASDAQ:AQST) and Zai Lab (NASDAQ:ZLAB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

Aquestive Therapeutics has higher earnings, but lower revenue than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Aquestive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aquestive Therapeutics	$44.54M	11.24	-$83.78M	-$0.61	N/A
Zai Lab	$460.16M	4.25	-$175.54M	-$1.62	N/A

In the previous week, Zai Lab had 3 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 6 mentions for Zai Lab and 3 mentions for Aquestive Therapeutics. Aquestive Therapeutics' average media sentiment score of 0.82 beat Zai Lab's score of 0.26 indicating that Aquestive Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aquestive Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zai Lab	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aquestive Therapeutics has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market. Comparatively, Zai Lab has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

Aquestive Therapeutics currently has a consensus target price of $8.80, suggesting a potential upside of 120.55%. Zai Lab has a consensus target price of $45.83, suggesting a potential upside of 165.55%. Given Zai Lab's higher probable upside, analysts plainly believe Zai Lab is more favorable than Aquestive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00
Zai Lab	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.63

32.5% of Aquestive Therapeutics shares are owned by institutional investors. Comparatively, 41.7% of Zai Lab shares are owned by institutional investors. 6.8% of Aquestive Therapeutics shares are owned by company insiders. Comparatively, 4.9% of Zai Lab shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Zai Lab has a net margin of -39.29% compared to Aquestive Therapeutics' net margin of -137.08%. Aquestive Therapeutics' return on equity of 0.00% beat Zai Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aquestive Therapeutics	-137.08%	N/A	-49.33%
Zai Lab	-39.29%	-24.32%	-15.52%

Summary

Aquestive Therapeutics beats Zai Lab on 10 of the 16 factors compared between the two stocks.

How does Aquestive Therapeutics compare to HUTCHMED?

Aquestive Therapeutics (NASDAQ:AQST) and HUTCHMED (NASDAQ:HCM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Aquestive Therapeutics presently has a consensus price target of $8.80, suggesting a potential upside of 120.55%. HUTCHMED has a consensus price target of $16.80, suggesting a potential upside of 54.55%. Given Aquestive Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Aquestive Therapeutics is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00
HUTCHMED	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40

Aquestive Therapeutics has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.26, meaning that its share price is 74% less volatile than the broader market.

HUTCHMED has higher revenue and earnings than Aquestive Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aquestive Therapeutics	$44.54M	11.24	-$83.78M	-$0.61	N/A
HUTCHMED	$548.51M	3.46	$456.91M	N/A	N/A

HUTCHMED has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -137.08%.

Company	Net Margins	Return on Equity	Return on Assets
Aquestive Therapeutics	-137.08%	N/A	-49.33%
HUTCHMED	N/A	N/A	N/A

In the previous week, Aquestive Therapeutics had 2 more articles in the media than HUTCHMED. MarketBeat recorded 3 mentions for Aquestive Therapeutics and 1 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 1.32 beat Aquestive Therapeutics' score of 0.82 indicating that HUTCHMED is being referred to more favorably in the news media.

Company	Overall Sentiment
Aquestive Therapeutics	Positive
HUTCHMED	Positive

32.5% of Aquestive Therapeutics shares are owned by institutional investors. Comparatively, 8.8% of HUTCHMED shares are owned by institutional investors. 6.8% of Aquestive Therapeutics shares are owned by company insiders. Comparatively, 3.6% of HUTCHMED shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Aquestive Therapeutics beats HUTCHMED on 9 of the 14 factors compared between the two stocks.

How does Aquestive Therapeutics compare to Mesoblast?

Aquestive Therapeutics (NASDAQ:AQST) and Mesoblast (NASDAQ:MESO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

Mesoblast has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -137.08%.

Company	Net Margins	Return on Equity	Return on Assets
Aquestive Therapeutics	-137.08%	N/A	-49.33%
Mesoblast	N/A	N/A	N/A

Aquestive Therapeutics presently has a consensus price target of $8.80, indicating a potential upside of 120.55%. Given Aquestive Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Aquestive Therapeutics is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00
Mesoblast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Aquestive Therapeutics has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market. Comparatively, Mesoblast has a beta of 2.05, suggesting that its share price is 105% more volatile than the broader market.

In the previous week, Aquestive Therapeutics and Aquestive Therapeutics both had 3 articles in the media. Aquestive Therapeutics' average media sentiment score of 0.82 beat Mesoblast's score of 0.74 indicating that Aquestive Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aquestive Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mesoblast	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

32.5% of Aquestive Therapeutics shares are owned by institutional investors. Comparatively, 1.4% of Mesoblast shares are owned by institutional investors. 6.8% of Aquestive Therapeutics shares are owned by company insiders. Comparatively, 18.8% of Mesoblast shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Aquestive Therapeutics has higher revenue and earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than Aquestive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aquestive Therapeutics	$44.54M	11.24	-$83.78M	-$0.61	N/A
Mesoblast	$17.20M	103.87	-$102.14M	-$0.54	N/A

Summary

Aquestive Therapeutics beats Mesoblast on 9 of the 15 factors compared between the two stocks.

Get Aquestive Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AQST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AQST vs. The Competition

Export

Metric	Aquestive Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$500.55M	$2.96B	$6.50B	$11.95B
Dividend Yield	N/A	1.77%	2.67%	5.61%
P/E Ratio	-6.54	12.38	20.85	21.87
Price / Sales	11.24	289.23	500.87	105.21
Price / Cash	N/A	56.16	43.05	54.72
Price / Book	-14.25	3.88	10.43	6.70
Net Income	-$83.78M	$75.85M	$3.56B	$337.26M
7 Day Performance	-0.99%	-1.87%	-1.39%	-1.41%
1 Month Performance	-7.64%	-6.20%	0.86%	1.15%
1 Year Performance	11.45%	12.60%	19.42%	22.61%

Aquestive Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AQST Aquestive Therapeutics	2.2232 of 5 stars	$3.99 flat	$8.80 +120.6%	+12.7%	$500.55M	$44.54M	N/A	160
TRVI Trevi Therapeutics	2.5936 of 5 stars	$14.16 -2.0%	$22.90 +61.7%	+112.0%	$2.01B	N/A	N/A	20
TYRA Tyra Biosciences	2.8906 of 5 stars	$33.37 +2.1%	$46.50 +39.3%	+152.8%	$2.00B	N/A	N/A	20	Positive News Analyst Forecast
ZLAB Zai Lab	2.8509 of 5 stars	$17.63 -4.6%	$45.83 +160.0%	-56.0%	$2.00B	$460.16M	N/A	1,784
HCM HUTCHMED	3.2336 of 5 stars	$11.44 +1.9%	$16.80 +46.9%	-33.4%	$2.00B	$548.51M	N/A	1,796	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AQST) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aquestive Therapeutics (AQST) Competitors

AQST vs. TRVI, TYRA, ZLAB, HCM, and MESO

How does Aquestive Therapeutics compare to Trevi Therapeutics?

Summary

How does Aquestive Therapeutics compare to Tyra Biosciences?

Summary

How does Aquestive Therapeutics compare to Zai Lab?

Summary

How does Aquestive Therapeutics compare to HUTCHMED?

Summary

How does Aquestive Therapeutics compare to Mesoblast?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AQST vs. The Competition

Aquestive Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aquestive Therapeutics (AQST) Competitors

AQST vs. TRVI, TYRA, ZLAB, HCM, and MESO

How does Aquestive Therapeutics compare to Trevi Therapeutics?

Which has more risk & volatility, TRVI or AQST?

Which has higher valuation & earnings, TRVI or AQST?

Is TRVI or AQST more profitable?

Do analysts prefer TRVI or AQST?

Does the media refer more to TRVI or AQST?

Do institutionals and insiders have more ownership in TRVI or AQST?

Summary

How does Aquestive Therapeutics compare to Tyra Biosciences?

Do insiders and institutionals hold more shares of AQST or TYRA?

Is AQST or TYRA more profitable?

Which has more risk & volatility, AQST or TYRA?

Do analysts recommend AQST or TYRA?

Which has preferable valuation and earnings, AQST or TYRA?

Does the media prefer AQST or TYRA?

Summary

How does Aquestive Therapeutics compare to Zai Lab?

Which has stronger earnings & valuation, AQST or ZLAB?

Does the media prefer AQST or ZLAB?

Which has more volatility & risk, AQST or ZLAB?

Do analysts recommend AQST or ZLAB?

Do insiders & institutionals hold more shares of AQST or ZLAB?

Is AQST or ZLAB more profitable?

Summary

How does Aquestive Therapeutics compare to HUTCHMED?

Do analysts recommend AQST or HCM?

Which has more volatility and risk, AQST or HCM?

Which has better valuation & earnings, AQST or HCM?

Is AQST or HCM more profitable?

Does the media favor AQST or HCM?

Do insiders and institutionals hold more shares of AQST or HCM?

Summary

How does Aquestive Therapeutics compare to Mesoblast?

Is AQST or MESO more profitable?

Do analysts recommend AQST or MESO?

Which has more risk & volatility, AQST or MESO?

Does the media refer more to AQST or MESO?

Do institutionals & insiders have more ownership in AQST or MESO?

Which has stronger earnings and valuation, AQST or MESO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AQST vs. The Competition

Aquestive Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools